Ignite Creation Date:
2024-05-05 @ 11:21 PM
Last Modification Date:
2024-10-26 @ 10:33 AM
Study NCT ID:
NCT01318421
Status:
TERMINATED
Last Update Posted:
2015-12-14
First Post:
2011-03-08
Brief Title:
A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Sponsor:
Elan Pharmaceuticals
Organization:
Elan Pharmaceuticals
Study Overview
Official Title:
An Open-Label Long-Term Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Status:
TERMINATED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis MS after participation in study MS103
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None